Product Overview
Ingredients:
Rabeprazole Sodium
Appearance:
This product is an enteric-coated tablet, appearing white or light yellow after removal of the coating.
Indications:
Gastric and duodenal ulcers, anastomotic ulcers, reflux esophagitis, and Zollinger-Ellison syndrome. Used as an adjunct to Helicobacter pylori eradication in patients with gastric and duodenal ulcers.
Dosage and Administration:
Gastric ulcers, duodenal ulcers, anastomotic ulcers, and Zollinger-Ellison syndrome: Generally, adults take 10 mg of this product orally once daily; 20 mg can be taken orally once daily depending on the condition. Generally, the treatment course for gastric and anastomotic ulcers should not exceed 8 weeks, and for duodenal ulcers should not exceed 6 weeks. Reflux esophagitis: Generally, adults take 10 mg of this product orally once daily; 20 mg can be taken orally once daily depending on the condition. Generally, the treatment course for reflux esophagitis should not exceed 8 weeks. For maintenance treatment of persistent and recurrent reflux esophagitis, take 10 mg of this product orally once daily. It can also be used as an adjunct to eradication of Helicobacter pylori in patients with gastric or duodenal ulcers. Generally, adults take 10 mg of this product orally, along with 750 mg of amoxicillin and 200 mg of clarithromycin twice daily for seven consecutive days. The clarithromycin dose can be increased as needed, up to a maximum of 400 mg twice daily. Note: For severe, recurrent, or intractable cases, 20 mg of this product orally once daily is recommended (except for maintenance treatment of recurrent reflux esophagitis).
Dosage and Intake:
Can be taken on an empty stomach or after a meal: Swallow the tablet whole.
Adverse Reactions:
According to international literature: Serious side effects: Shock: Allergic reactions and shock have been reported with this product. If any abnormality is observed, discontinue use immediately and seek appropriate treatment. Blood: This product rarely causes various blood cell reductions, thrombocytopenia, granulocytopenia, hemolytic anemia, etc. However, it may occasionally cause granulocytopenia, anemia, etc. If any abnormality is found, stop taking the drug immediately and seek treatment. Visual impairment: There have been reports of visual impairment when taking this drug abroad. The most common adverse reactions are headache, diarrhea, and nausea. Other adverse reactions include rhinitis, abdominal pain, weakness, flatulence, pharyngitis, vomiting, nonspecific pain or back pain, dizziness, flu symptoms, infectious cough, constipation, and insomnia. Adverse reactions include itching, rash, palpitations, myalgia, chest pain, dry mouth, indigestion, nervous hypersensitivity, drowsiness, bronchitis, sinusitis, chills, belching, leg cramps, urinary tract infection, arthritis and fever, limb weakness, numbness, decreased grip strength, unsteady gait, and fatigue. Rare adverse reactions include anorexia, gastritis, weight gain, depression, pruritus, visual/olfactory dysfunction, stomatitis, diaphoresis, and leukocytosis. Elevated liver enzymes, such as ALT, AST, AI-P, γ-GTP, LDH, and total bilirubin, have been reported in 2% of patients. Bullous rash or other skin reactions, including erythema, have been reported. If skin lesions occur, the drug should be discontinued immediately.
Contraindications:
1. Patients with a history of hypersensitivity to any component of this product. 2. Patients currently taking atazanavir sulfate.
Precautions:
1. Symptoms treated with rabeprazole sodium do not exclude the possibility of gastric or esophageal cancer. Therefore, the possibility of cancer should be ruled out before initiating treatment with this product. Although no significant drug-related safety issues have been identified in age- and sex-matched studies comparing patients with mild to moderate hepatic impairment to healthy controls, physicians recommend that patients with severe hepatic impairment exercise particular caution when initially using this product. 2. While taking this product, regular blood tests and blood biochemistry (such as liver enzyme tests) should be performed. If abnormalities are detected, discontinue use and seek prompt treatment. 3. Use with caution in patients with impaired liver function.
Overdose:
This study has not been conducted and no reliable references are available.
Targeted Use:
There is a lack of clinical experience and safety data for this product in children, so its use is not recommended. Elderly individuals should use this product with caution. This product is primarily metabolized in the liver, and elderly individuals generally have reduced liver function, making adverse reactions more likely. Therefore, if adverse reactions occur, measures such as temporarily discontinuing the drug/increasing the rest interval and monitoring should be implemented. Pregnant women or women who may become pregnant should only use this product when the benefits clearly outweigh the risks. Breastfeeding women should avoid using this product. If necessary, breastfeeding should be discontinued.
Drug Interactions:
Concomitant use with atazanavir is contraindicated. Use with caution with digoxin, methyldigoxin, itraconazole, gefitinib, or antacids containing aluminum hydroxide gel/magnesium hydroxide.
Manufacturer:
Jincheng Haisi Pharmaceutical Co., Ltd.
